Phase 2 Study of Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy in Patients With Resectable Pancreatic Cancer

PURPOSE: Long-term survival rates for patients with resected pancreatic ductal adenocarcinoma (PDAC) have stagnated at 20% for more than a decade, demonstrating the need to develop novel adjuvant therapies. Gemcitabine-erlotinib therapy has demonstrated a survival benefit for patients with metastati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Radiat Oncol Biol Phys
Hlavní autoři: Herman, Joseph M., Fan, Katherine Y., Wild, Aaron T., Hacker-Prietz, Amy, Wood, Laura D., Blackford, Amanda L., Ellsworth, Susannah, Zheng, Lei, Le, Dung T., De Jesus-Acosta, Ana, Hidalgo, Manuel, Donehower, Ross C., Schulick, Richard D., Edil, Barish H., Choti, Michael A., Hruban, Ralph H., Pawlik, Timothy M., Cameron, John L., Laheru, Daniel A., Wolfgang, Christopher L.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4322929/
https://ncbi.nlm.nih.gov/pubmed/23773391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijrobp.2013.03.032
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky